Predilife SA Raises €900k Convertible Bonds, Gains FDA Nod on DenSeeRisk

Predilife SA’s Recent Corporate and Regulatory Developments

Convertible Bond Offering and Capital Raise

Predilife SA announced on 10 April 2026 the launch of a convertible bond issue with a coupon rate of 8.5 % per annum. The offering, which has already secured a funding tranche of approximately €900 000, is structured as a public offering of convertible bonds that may be redeemed in full either in cash or in shares at the issuer’s discretion. The proceeds will be used to support the company’s industrial and financial strategy, as detailed in the accompanying press release that outlines plans for product development and commercialization in the biotechnology sector.

FDA Interaction Regarding DenSeeRisk

On the same day, the company reported a return from the U.S. Food and Drug Administration (FDA) concerning the regulatory submission for DenSeeRisk, a medical device that integrates the MammoRisk platform with artificial‑intelligence‑based mammography analysis. The FDA’s feedback marks an important regulatory milestone for the device, potentially accelerating its path to market approval.

Validation of MammoRisk Strategy

In addition to the FDA update, Predilife SA highlighted a scientific breakthrough in breast‑cancer detection. The company confirmed the validation of its overall MammoRisk strategy, reinforcing the clinical credibility of its risk‑assessment platform. This validation supports the company’s positioning within the oncology diagnostics arena and underpins its future commercial strategy.

Financial Snapshot

The recent bond issuance and regulatory developments are integral to Predilife SA’s broader strategy to expand its biotechnology portfolio and secure additional capital for research, development, and commercialization activities.